MHRA Approves Vyjuvek for Dystrophic Epidermolysis Bullosa
On 15 May 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, approved beremagene geperpavec, sold as Vyjuvek, for the treatment of wounds in people with dystrophic epidermolysis bullosa, usually shortened to DEB. According to the government announcement, it can be used from birth, which matters because this is a condition many families are dealing with from a baby’s earliest days. If you are coming to this story for the first time, the key point is simple. This is not a general cream for sore skin. It is a treatment aimed at a rare inherited condition that can leave skin extremely fragile and wounds difficult to heal.
If you are hearing about DEB for the first time, start here. The condition is caused by a fault in a gene that helps hold layers of skin together. When that instruction is not working properly, the skin can blister or tear much more easily than most people’s skin would. That is why DEB is not just a matter of having sensitive skin. It can mean repeated wounds, pain, dressings, infections and a daily routine shaped around avoiding damage. For patients, parents and carers, ordinary tasks such as washing, getting dressed, sleeping or moving around can take much more care than most of us ever have to think about.
If the phrase gene therapy sounds intimidating, it helps to slow it down. The MHRA says Vyjuvek is a gel that is applied directly to wounds. It works by delivering a copy of the gene into cells in the wound to help the skin heal. The regulator also made an important point that is easy to lose in dramatic headlines: the modified virus and genetic material in this medicine do not change the patient’s DNA. That does not answer every question a family might have, but it does make the treatment easier to understand. This is a wound-applied medicine designed to support healing where the skin is damaged.
The evidence behind the approval comes from a study involving 31 patients aged 1 to 44 with dystrophic epidermolysis bullosa. In that study, 67% of wounds treated with Vyjuvek were completely healed at six months, compared with 22% of wounds treated with placebo. What that means, in plain English, is that researchers compared the medicine with a version that did not contain the active treatment. The difference between 67% and 22% is why this approval is being treated as an important step. The study was small, but rare conditions often involve smaller trials because there are far fewer patients to recruit in the first place.
Approval from the MHRA does not mean a medicine is perfect, and the agency did not pretend otherwise. It means the regulator reviewed the evidence and decided that, for this use, the benefits were strong enough to justify the risks. Julian Beach, the MHRA’s Executive Director of Healthcare Quality and Access, said the decision gives people living with dystrophic epidermolysis bullosa a new treatment option. He also said the agency will continue to monitor the safety and effectiveness of beremagene geperpavec as it is used more widely. That ongoing checking matters. In medicines regulation, approval is not the end of scrutiny; it is the point where wider real-world monitoring begins.
There is also a regulatory detail here that is worth translating. The government notice says the product was submitted and approved through the International Recognition Procedure, often shortened to IRP. You can think of this as a route that allows the UK regulator to consider evidence and decisions from trusted regulators elsewhere while still making its own decision. For readers trying to make sense of the acronyms, this is the wider lesson: when the MHRA approves a medicine, it is saying the product has been reviewed for quality, safety and how well it works. That does not remove uncertainty, especially with newer treatments, but it does mean the decision has gone through a formal regulatory process rather than publicity alone.
The approval was granted to Krystal Biotech Netherlands, B.V. on 15 May 2026. The MHRA also says fuller product documents, including the Summary of Product Characteristics and the Patient Information Leaflet, will be published on its products website within seven days of approval. That is where clinicians and patients can look for the formal wording on use, warnings and reported side effects. For families affected by DEB, this news will not make the condition disappear. But it does add something rare disease communities often wait years to see: another treatment option, backed by a regulator, with evidence that more wounds healed than they did without the medicine. In a condition where everyday skin damage can shape everyday life, that is not a small development.